Literature DB >> 31489308

Nonalcoholic steatohepatitis pharmacotherapy and predictors of response: dual role of aminotransferases as biosensors of metabolism and biomarkers of histological improvement.

Silvia Sookoian1,2, Carlos J Pirola1,3.   

Abstract

Entities:  

Year:  2019        PMID： 31489308      PMCID： PMC6700013          DOI： 10.21037/hbsn.2019.02.04

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

1.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 4.  Pharmacotherapy for NASH: Current and emerging.

Authors:  Monica A Konerman; Jacob C Jones; Stephen A Harrison
Journal:  J Hepatol       Date:  2017-11-06       Impact factor: 25.083

5.  Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study.

Authors:  Stacy A Porter; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Caroline S Fox
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

6.  Bile acid sequestrants for lipid and glucose control.

Authors:  Bart Staels; Yehuda Handelsman; Vivian Fonseca
Journal:  Curr Diab Rep       Date:  2010-02       Impact factor: 4.810

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Vincent W-S Wong; Valerio Nobili; Christopher P Day; Silvia Sookoian; Jacquelyn J Maher; Elisabetta Bugianesi; Claude B Sirlin; Brent A Neuschwander-Tetri; Mary E Rinella
Journal:  Nat Rev Dis Primers       Date:  2015-12-17       Impact factor: 52.329

8.  Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level.

Authors:  Silvia Sookoian; Gustavo O Castaño; Romina Scian; Tomas Fernández Gianotti; Hernán Dopazo; Cristian Rohr; Graciela Gaj; Julio San Martino; Ina Sevic; Diego Flichman; Carlos J Pirola
Journal:  Am J Clin Nutr       Date:  2016-01-20       Impact factor: 7.045

Review 9.  Mechanisms of NAFLD development and therapeutic strategies.

Authors:  Scott L Friedman; Brent A Neuschwander-Tetri; Mary Rinella; Arun J Sanyal
Journal:  Nat Med       Date:  2018-07-02       Impact factor: 53.440

Review 10.  Alanine aminotransferase in clinical practice. A review.

Authors:  K E Sherman
Journal:  Arch Intern Med       Date:  1991-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.